DocMorris AG (OTCMKTS:ZRSEF – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 643,190 shares, an increase of 724.0% from the June 30th total of 78,057 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the company. UBS Group raised DocMorris from a “sell” rating to a “neutral” rating in a research note on Monday, July 20th. Deutsche Bank Aktiengesellschaft raised shares of DocMorris from a “hold” rating to a “buy” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, DocMorris currently has a consensus rating of “Moderate Buy”.
Get Our Latest Stock Analysis on ZRSEF
DocMorris Stock Performance
DocMorris Company Profile
DocMorris is a leading European online pharmacy brand and a subsidiary of the Swiss-based Zur Rose Group (OTCMKTS:ZRSEF). Through its digital platform, the company offers mail-order dispensing of prescription medications and over-the-counter health products directly to consumers’ homes.
The company’s core services include the online sale and delivery of prescription and non-prescription drugs, health supplements, personal care items and medical devices. Leveraging its e-commerce infrastructure and proprietary pharmacy management systems, DocMorris also provides digital health solutions such as telemedicine consultations, medication management tools and mobile app-based healthcare services.
Originally launched in the early 2000s in Germany, DocMorris has expanded its reach to serve customers in multiple European countries, including the Netherlands, Belgium, Luxembourg and Switzerland.
Featured Stories
- Five stocks we like better than DocMorris
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for DocMorris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocMorris and related companies with MarketBeat.com's FREE daily email newsletter.
